<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tempus Ai, Inc. — News on 6ix</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock</link>
<description>Latest news and press releases for Tempus Ai, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 27 May 2026 12:33:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tempus-ai-inc-class-a-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c8aa78dffbe2df11bf75.webp</url>
<title>Tempus Ai, Inc.</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock</link>
</image>
<item>
<title>Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-upgrades-its-smart-physician-platform-hub-with-next-generation-agentic-ai-architecture-to-streamline-clinical-workflows</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-upgrades-its-smart-physician-platform-hub-with-next-generation-agentic-ai-architecture-to-streamline-clinical-workflows</guid>
<pubDate>Wed, 27 May 2026 12:33:00 GMT</pubDate>
<description>CHICAGO, May 27, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities wit</description>
</item>
<item>
<title>Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-37-abstracts-accepted-for-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-37-abstracts-accepted-for-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting</guid>
<pubDate>Tue, 26 May 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, May 26, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois.</description>
</item>
<item>
<title>Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-expands-strategic-collaboration-with-bristol-myers-squibb-to-enhance-the-probability-of-success-across-clinical-development-programs-in-oncology-and-neuroscience</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-expands-strategic-collaboration-with-bristol-myers-squibb-to-enhance-the-probability-of-success-across-clinical-development-programs-in-oncology-and-neuroscience</guid>
<pubDate>Thu, 14 May 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a</description>
</item>
<item>
<title>Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution"</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambry-genetics-care-programr-wins-2026-medtech-breakthrough-award-for-best-overall-health-informatics-solution</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambry-genetics-care-programr-wins-2026-medtech-breakthrough-award-for-best-overall-health-informatics-solution</guid>
<pubDate>Mon, 11 May 2026 10:00:00 GMT</pubDate>
<description>ALISO VIEJO, Calif., May 11, 2026--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and Education) has been awarded "Best Overall Health Informatics Solution" in the 10th Annual MedTech Breakthrough Awards. The global program recognizes excellence in digital health and medical technology, selecting CARE from more than 5,000 nominations worldwide.</description>
</item>
<item>
<title>Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-pricing-of-upsized-offering-of-dollar4000-million-of-convertible-senior-notes</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-pricing-of-upsized-offering-of-dollar4000-million-of-convertible-senior-notes</guid>
<pubDate>Fri, 08 May 2026 04:59:00 GMT</pubDate>
<description>CHICAGO, May 08, 2026--Tempus AI, Inc. ("Tempus") (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "Notes") in a private placement (the "Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggreg</description>
</item>
<item>
<title>Tempus Reports First Quarter 2026 Results</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reports-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reports-first-quarter-2026-results</guid>
<pubDate>Tue, 05 May 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care,</description>
</item>
<item>
<title>Tempus to Host Inaugural Investor Day on May 29, 2026</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-host-inaugural-investor-day-on-may-29-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-host-inaugural-investor-day-on-may-29-2026</guid>
<pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 29, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus’ leadership team, including, Founder and CEO Eric Lefkofsky, Chief Financial Officer Jim Rogers, CEO of Data and Applications Ryan Fukushima, CEO of Diagnostics Tom Schoenherr, and Chief Scientific Officer</description>
</item>
<item>
<title>Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-named-to-times-10-most-influential-health-and-life-science-companies-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-named-to-times-10-most-influential-health-and-life-science-companies-of-2026</guid>
<pubDate>Tue, 28 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 28, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation.</description>
</item>
<item>
<title>Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 23, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to transform care delivery across more than 1.5 million annual patient visits to the USC Norris Comprehensive Cancer Center, the</description>
</item>
<item>
<title>Tempus to Report First Quarter 2026 Financial Results on May 5</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-report-first-quarter-2026-financial-results-on-may-5</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-report-first-quarter-2026-financial-results-on-may-5</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 21, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026.</description>
</item>
<item>
<title>Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-predicta-biosciences-announce-collaboration-to-expand-life-sciences-access-to-ultrasensitive-whole-genome-sequencing-assay-for-hematologic-malignancies-and-mrd-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-predicta-biosciences-announce-collaboration-to-expand-life-sciences-access-to-ultrasensitive-whole-genome-sequencing-assay-for-hematologic-malignancies-and-mrd-monitoring</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta</description>
</item>
<item>
<title>Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-31-abstracts-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-31-abstracts-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an</description>
</item>
<item>
<title>Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-present-at-the-25th-annual-needham-virtual-healthcare-conference-1</guid>
<pubDate>Wed, 08 Apr 2026 20:01:00 GMT</pubDate>
<description>CHICAGO, April 08, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16.</description>
</item>
<item>
<title>Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the</description>
</item>
<item>
<title>Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-blood-cancer-unitedr-announce-collaboration-to-develop-one-of-the-largest-pediatric-acute-myeloid-leukemia-real-world-data-registries</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-blood-cancer-unitedr-announce-collaboration-to-develop-one-of-the-largest-pediatric-acute-myeloid-leukemia-real-world-data-registries</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, March 17, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.</description>
</item>
<item>
<title>Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine</guid>
<pubDate>Tue, 03 Mar 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, March 03, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.</description>
</item>
<item>
<title>Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, February 26, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST.</description>
</item>
</channel>
</rss>